PTHrP类似物影响绝经后妇女骨质疏松症的骨代谢
PTHrP Analogues Affect Bone Metabolism in Postmenopausal Women with Osteoporosis
摘要: 骨质疏松症和脆性骨折是相关联的健康问题，其致残患者较其他慢性病患者住院时间长，相关的医疗费用正以惊人的速度递增。甲状旁腺激素和甲状旁腺激素相关蛋白类似物，无论是作为单一疗法、与抗再吸收剂联合使用，还是与抗再吸收剂联用，都可能在骨质疏松症管理中发挥越来越大的作用。对于绝经后妇女的临床评估骨质减少、早期干预及管理是必要且重要的，将对PTHrP类似物阿巴洛肽在骨质疏松症的作用做一综述。
Abstract: Osteoporosis and fragility fractures are associated health problems, and their disabled patients have longer hospital stays than other patients with chronic diseases, and the related medical costs are increasing at an alarming rate. Parathyroid hormone and parathyroid hormone-related protein analogues, whether as monotherapy, in combination with anti-resorptive agents, or in combination with anti-resorptive agents, are likely to play an increasing role in osteoporosis management. Clinical evaluation of osteopenia, early intervention and management in postmenopausal women is necessary and important, and the role of the PTHrP analogue abalopeptide in osteoporosis will be reviewed.
文章引用：赵研, 许慧宁. PTHrP类似物影响绝经后妇女骨质疏松症的骨代谢[J]. 临床医学进展, 2022, 12(5): 4127-4131. https://doi.org/10.12677/ACM.2022.125598

参考文献

[1] 马远征, 王以朋, 刘强, 等. 中国老年骨质疏松症诊疗指南(2018) [J]. 中国骨质疏松杂志, 2018, 24(12): 1541-1567.
[2] Sözen, T., Özışık, L. and Başaran, N.Ç. (2017) An Overview and Management of Osteoporosis. Eu-ropean Journal of Rheumatology, 4, 46-56. [Google Scholar] [CrossRef] [PubMed]
[3] 夏维波, 章振林, 林华, 等. 原发性骨质疏松症诊疗指南(2017) [J]. 中国骨质疏松杂志, 2019, 25(3): 281-309.
[4] Zebaze, R.M., Ghasem-Zadeh, A., Bohte, A., 等. 女性桡骨远端和死后股骨的皮质内重塑和孔隙率: 一项横断面研究[J]. 柳叶刀, 2010, 375: 1729-1736.
[5] Kanis, J.A., Johnell, O., Oden, A., et al. (2000) Long-Term Risk of Osteoporotic Fracture in Malmö. Osteoporosis International, 11, 669-674. [Google Scholar] [CrossRef] [PubMed]
[6] 雷欣东, 于慧, 龙琼, 等. 绝经后骨质疏松症发病机制研究进展[J]. 中国骨质疏松杂志, 2021, 27(11): 1681-1684.
[7] Kraenzlin, M.E. and Meier, C. (2011) Parathyroid Hormone Analogues in the Treatment of Osteoporosis. Nature Reviews Endocri-nology, 7, 647-656. [Google Scholar] [CrossRef] [PubMed]
[8] García-Martín, A., Ardura, J.A., Maycas, M., et al. (2014) Functional Roles of the Nuclear Localization Signal of Parathyroid Hormone-Related Protein (PTHrP) in Os-teoblastic Cells. Molecular Endocrinology, 28, 925-934. [Google Scholar] [CrossRef] [PubMed]
[9] Miller, P.D., Hattersley, G., Riis, B.J., et al. (2016) Effect of Abalo-paratide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial. JAMA, 316, 722-733. [Google Scholar] [CrossRef] [PubMed]
[10] Hattersley, G., Dean, T., Corbin, B.A., et al. (2016) Binding Selec-tivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology, 157, 141-149. [Google Scholar] [CrossRef] [PubMed]
[11] Dempster, D.W., Zhou, H., Rao, S.D., et al. (2021) Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women with Osteoporosis. Journal of Bone and Mineral Research, 36, 644-653. [Google Scholar] [CrossRef] [PubMed]
[12] Kendler, D.L., Marin, F., Zerbini, C.A.F., et al. (2018) Effects of Teripar-atide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. The Lancet, 391, 230-240. [Google Scholar] [CrossRef] 
[13] Leder, B.Z., Mitlak, B., Hu, M.Y., et al. (2020) Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 105, 938-943. [Google Scholar] [CrossRef] [PubMed]
[14] Majumdar, S.R., Leslie, W.D., Lix, L.M., et al. (2016) Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. The Journal of Clinical Endocri-nology & Metabolism, 101, 4489-4496. [Google Scholar] [CrossRef] [PubMed]
[15] Rubin, M.R. and Patsch, J.M. (2016) Assessment of Bone Turnover and Bone Quality in Type 2 Diabetic Bone Disease: Current Concepts and Future Directions. Bone Research, 4, 16001. [Google Scholar] [CrossRef] [PubMed]
[16] Bilezikian, J.P., Hattersley, G., Fitzpatrick, L.A., et al. (2018) Abalo-paratide-SC Improves Trabecular Microarchitecture as Assessed by Trabecular Bone Score (TBS): A 24-Week Random-ized Clinical Trial. Osteoporosis International. 29, 323-328. [Google Scholar] [CrossRef] [PubMed]
[17] Sahbani, K., Cardozo, C.P., Bauman, W.A., et al. (2019) Abalo-paratide Exhibits Greater Osteoanabolic Response and Higher cAMP Stimulation and β-Arrestin Recruitment than Teri-paratide. Physiological Reports, 7, e14225. [Google Scholar] [CrossRef] [PubMed]
[18] Jolette, J., Attalla, B., Varela, A., et al. (2017) Comparing the Incidence of Bone Tumors in Rats Chronically Exposed to the Selective PTH Type 1 Receptor Agonist Abaloparatide or PTH(1-34). Regulatory Toxicology and Pharmacology, 86, 356-365. [Google Scholar] [CrossRef] [PubMed]
[19] Kanis, J.A., Cooper, C., Rizzoli, R., et al. (2017) Identification and Management of Patients at Increased Risk of Osteoporotic Fracture: Outcomes of an ESCEO Expert Consensus Meeting. Osteoporosis International, 28, 2023-2034. [Google Scholar] [CrossRef] [PubMed]
[20] Kanis, J.A., Cooper, C., Rizzoli, R., et al. (2018) Review of the Guideline of the American College of Physicians on the Treatment of Osteoporosis. Osteoporosis International, 29, 1505-1510. [Google Scholar] [CrossRef] [PubMed]
[21] 陈本川. 治疗绝经后骨质疏松症新药——阿巴洛肽(abaloparatide) [J]. 医药导报, 2018, 37(1): 138-142.

为你推荐